Tissue Regenix has maintained its strong performance, expecting to deliver 16% revenue growth over the first half period to June 2024, generating revenues of c$16.4m. This represents the seventh consecutive reporting period of revenue growth, with Tissue Regenix delivering an average of c20% revenue growth per period across these seven half-year intervals. Furthermore, the company expects its adjusted EBITDA to grow in H1/24 versus the H1/23 profit of $0.35m. We believe Tissue Regenix’s 4S Strat ....
